The complement system, which is made up of more than 30 serum and cell surface components, works with the innate and acquired immune systems to recognize and get rid of pathogens. Following the activation of the complement system, a series of events involving proteolysis and assembly lead to the cleavage of the third complement component (C3). The activation pathway refers to the cascade that leads to C3 cleavage. The classical, lectin, and alternative pathways are the three types of activation.
The complement cascade is a double-edged sword that causes phagocytosis and inflammation while also providing defense against viral and bacterial invasion. If complement is not properly controlled, it can cause significant pathological damage to erythrocytes (hemolysis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and blood vessels (vasculitis).
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V32062 | Danicopan (ACH-4471) | 1903768-17-1 | Danicopan(ACH4471) is a novel, selective and orally bioavailable small-molecule factor D inhibitor, which inhibits alternative pathway of complement (APC) activity. |
|
V33581 | EG00229 TFA | 1210945-69-9 | EG-00229 TFA, the trifluoroacetic acid form of EG00229, is a novel and potent Neuropilin 1 (NRP1) receptor antagonist with antitumor effects. |
|
V74776 | EG01377 dihydrochloride | 2749438-61-5 | EG01377 di-HCl is a potent, bioavailable and selective neuropilin-1 (NRP1) inhibitor (antagonist) with a Kd of 1.32 μM and IC50 of 609 nM for both NRP1-a1 and NRP1-b1. |
|
V60097 | Entadamide-A-β-D-glucopyranoside | 138916-58-2 | Entadamide-A-β-D-glucopyranoside is one of the major components of Phaseolus vulgaris seeds. |
|
V74786 | Factor B-IN-1 | 1481631-75-7 | Factor B-IN-1 is a Factor B inhibitor. |
|
V74785 | Factor D inhibitor 6 | 1386455-51-1 | Factor D inhibitor 6 is a specific, orally bioactive factor D (factor D) inhibitor (antagonist) with IC50 of 30 nM and a Kd of 6 nM. |
|
V74787 | Gefurulimab (ALXN-1720) | 2456407-94-4 | Gefurulimab (ALXN-1720) is a human bispecific antibody against complement C5 and albumin that binds to C5 and prevents its activation. |
|
V74788 | IONIS-FB-LRx (RG6299) | 2272975-74-1 | IONIS-FB-LRx is a specialized antisense oligonucleotide (ASO) targeting complement factor B (CFB). |
|
|
V80391 | IONIS-FB-LRx sodium (RG6299 sodium) | IONIS-FB-LRx sodium is a specialized antisense oligonucleotide (ASO) targeting complement factor B (CFB). | |
|
V2514 | Iptacopan (LNP023) hydrochloride | 1646321-63-2 | Iptacopan (LNP-023;LNP023) HCl, the hydrochloride salt ofIptacopan,is an oral, potent and selective factor B inhibitor ( IC50 = 10 nM). |
|
V51028 | JPE-1375 | 1254036-23-1 | JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. |
|
V74796 | L-156602 (Antibiotic L 156602; PD 124966) | 125228-51-5 | L-156602 is a C5a receptor antagonist. |
|
V74794 | Lampalizumab (RG 7417; TNX 234; Anti-CFD Recombinant Antibody) | 1278466-20-8 | Lampalizumab (RG 7417) is a human monoclonal antibody (mAb) that targets complement factor D (Factor D) in the complement pathway. |
|
V74782 | Lipoteichoic acid | 56411-57-5 | Lipoteichoic acid is a component of the cell wall of Staphylococcus aureus and activates the complement system by inducing C3 and inhibiting CD55. |
|
|
V76703 | NH2-C6-ARC186 sodium | NH2-C6-ARC186 sodium is an ARC186 with an NH2-C6 linker that can be coupled to other peptides or molecules. | |
|
V74792 | Olendalizumab (ALXN1007) | 2210314-30-8 | Olendalizumab (ALXN1007) is a humanized mouse-derived IgG2-G4-κ antibody targeting complement protein C5a (Ki=60 pM). |
|
V60096 | Phaseoloidin | 118555-82-1 | Phaseolin is a highly pure acid grain derived from tobacco caterpillars that helps plants resist lepidopteran herbivores. |
|
V76618 | PMX 205 Trifluoroacetate | PMX 205 Trifluoroacetate is a potent complement C5a receptor (C5aR; CD88) antagonist. | |
|
V74778 | POT-4 (AL-78898A) | 934461-40-2 | POT-4 (AL-78898A), a Compstatin analogue, is a potent inhibitor of complement factor C3 activation. |
|
V81176 | POT-4 TFA (AL-78898A TFA) | POT-4 TFA (AL-78898A TFA), a Compstatin analogue, is a potent inhibitor of complement factor C3 activation. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
